Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 20.48% is 175% above its 5-year average of 7.44%, near the high end of its 5-year range (-8.30%–20.48%).
As of the fiscal period ended Wednesday, December 31, 2025. 114.56% above its 12-month average of 9.54%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
20.48%
RETURN ON ASSETS (ROA) AVG TTM
9.54%
RETURN ON ASSETS (ROA) AVG 3Y
8.43%
RETURN ON ASSETS (ROA) AVG 5Y
7.44%
RETURN ON ASSETS (ROA) AVG 10Y
5.02%
RETURN ON ASSETS (ROA) AVG 15Y
1.09%
RETURN ON ASSETS (ROA) AVG 20Y
-7.51%
CURRENT VS TTM AVG
+114.56%
CURRENT VS 3Y AVG
+142.87%
CURRENT VS 5Y AVG
+175.15%
CURRENT VS 10Y AVG
+307.75%
CURRENT VS 15Y AVG
+1785.82%
CURRENT VS 20Y AVG
+372.74%
SECTOR MEDIAN · HEALTHCARE
4.76%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+330.25%
vs the sector median at left
Incyte Corporation
Market Cap
$24.28B
Return on Assets (ROA)
20.48%
TTM Avg
9.54%
3Y Avg
8.43%
5Y Avg
7.44%
Market Cap
$24.72B
Return on Assets (ROA)
13.86%
TTM Avg
12.54%
3Y Avg
14.20%
5Y Avg
14.86%
Market Cap
$23.16B
Return on Assets (ROA)
-6.03%
TTM Avg
-3.96%
3Y Avg
9.16%
5Y Avg
17.06%
Market Cap
$25.74B
Return on Assets (ROA)
5.41%
TTM Avg
4.41%
3Y Avg
4.42%
5Y Avg
6.18%
Market Cap
$26.03B
Return on Assets (ROA)
6.27%
TTM Avg
5.75%
3Y Avg
6.24%
5Y Avg
8.30%
Market Cap
$26.07B
Return on Assets (ROA)
0.67%
TTM Avg
13.34%
3Y Avg
15.53%
5Y Avg
17.15%
Market Cap
$22.32B
Return on Assets (ROA)
-28.75%
TTM Avg
-24.02%
3Y Avg
-10.32%
5Y Avg
-0.33%
Market Cap
$22.03B
Return on Assets (ROA)
19.17%
TTM Avg
16.59%
3Y Avg
14.73%
5Y Avg
13.22%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $24.28B | 20.48% | 9.54% | 8.43% | 7.44% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.72B | 13.86% | 12.54% | 14.20% | 14.86% |
| BioNTech SE (BNTX)vs › | $23.16B | -6.03% | -3.96% | 9.16% | 17.06% |
| Labcorp Holdings Inc. (LH)vs › | $25.74B | 5.41% | 4.41% | 4.42% | 6.18% |
| STERIS plc (STE)vs › | $22.68B | 7.29% | 6.68% | 4.44% | 4.33% |
| Quest Diagnostics Incorporated (DGX)vs › | $26.03B | 6.27% | 5.75% | 6.24% | 8.30% |
| Waters Corporation (WAT)vs › | $26.07B | 0.67% | 13.34% | 15.53% | 17.15% |
| Moderna, Inc. (MRNA)vs › | $22.32B | -28.75% | -24.02% | -10.32% | -0.33% |
| United Therapeutics Corporation (UTHR)vs › | $22.03B | 19.17% | 16.59% | 14.73% | 13.22% |
| Viatris Inc. (VTRS)vs › | $20.55B | -0.80% | -5.49% | -1.68% | -1.68% |
ROA
20.5%
ROE
25.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 18.49% |
| 2024-12-31 | 0.60% |
| 2023-12-31 | 8.81% |
| 2022-12-31 | 5.83% |
| 2021-12-31 | 19.23% |
| 2020-12-31 | -8.30% |
| 2019-12-31 | 13.04% |
| 2018-12-31 | 4.14% |
| 2017-12-31 | -13.60% |
| 2016-12-31 | 6.36% |
| 2015-12-31 | 0.65% |
| 2014-12-31 | -5.84% |
| 2013-12-31 | -13.21% |
| 2012-12-31 | -13.41% |
| 2011-12-31 | -56.71% |
| 2010-12-31 | -6.50% |
| 2009-12-31 | -29.74% |
| 2008-12-31 | -76.99% |
| 2007-12-31 | -31.51% |
| 2006-12-31 | -20.97% |
| 2005-12-31 | -27.54% |
| 2004-12-31 | -31.88% |
| 2003-12-31 | -43.86% |
| 2002-12-31 | -24.79% |
| 2001-12-31 | -25.97% |
| 2000-12-31 | -3.35% |
| 1999-12-31 | -12.08% |
| 1998-12-31 | 1.52% |
| 1997-12-31 | 3.57% |
| 1996-12-31 | -10.16% |
